Revenue and Profit - Revenue for Q1 2022 was CNY 226,514,694.52, an increase of 14.07% compared to CNY 198,572,194.45 in the same period last year[3] - Net profit attributable to shareholders was CNY 60,813,979.13, up 4.08% from CNY 58,429,472.14 year-on-year[3] - Total operating revenue for the first quarter was CNY 226,514,694.52, an increase of 14.1% compared to CNY 198,572,194.45 in the previous year[28] - The net profit for the first quarter was 60,813,599.46, an increase from 58,429,472.14 in the previous year, representing a growth of approximately 4.1%[34] - The total profit amounted to 67,159,336.82, compared to 66,538,342.17 in the same period last year, indicating a year-over-year increase of about 0.9%[34] - The basic and diluted earnings per share were both 0.2218, up from 0.2132 in the previous year, reflecting a growth of approximately 2.7%[34] - Operating profit for the quarter was 67,273,409.04, slightly higher than 66,638,884.70 from the previous year, showing an increase of about 1.0%[34] Cash Flow and Liquidity - Net cash flow from operating activities decreased by 263.85%, resulting in a net outflow of CNY 29,426,149.07 compared to a net inflow of CNY 17,958,783.92 in the previous year[3] - Cash flow from operating activities was negative at -29,426,149.07, a decline from a positive cash flow of 17,958,783.92 in the same quarter last year[38] - Cash and cash equivalents at the end of the reporting period amounted to RMB 501.36 million, an increase from RMB 460.70 million at the beginning of the year[18] - Cash and cash equivalents at the end of the period totaled 485,799,731.61, down from 748,490,191.17 at the end of the previous year[41] - The company reported a cash and cash equivalents balance of CNY 275,603.00, indicating liquidity management[21] - The company generated cash inflow from investment activities of 572,600,157.33, significantly higher than 59,300,000.00 in the previous year[38] - The company’s financial report indicates a significant increase in cash flow, reflecting strong liquidity management[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,359,733,681.74, a decrease of 0.67% from CNY 2,375,626,201.07 at the end of the previous year[3] - Total assets decreased to CNY 2,359,733,681.74 from CNY 2,375,626,201.07, a decline of 0.7%[27] - Total liabilities decreased to CNY 469,937,609.99 from CNY 499,277,247.97, a reduction of 5.9%[27] - Inventory increased to CNY 249,087,289.79 from CNY 237,300,858.83, reflecting a growth of 4.8%[21] - The company’s equity attributable to shareholders rose to CNY 1,889,790,810.07 from CNY 1,876,348,953.10, an increase of 0.7%[27] Shareholder Information and Repurchase - The total number of common shareholders at the end of the reporting period is 12,676, with the largest shareholder holding 28.01% of shares[12] - The company repurchased a total of 2,763,000 shares, accounting for 1.0015% of the total share capital, with a total payment of approximately RMB 48.04 million[17] - The company plans to use between RMB 50 million and RMB 100 million for share repurchase, with a maximum price of RMB 27.00 per share[17] - The largest shareholder, Shenzhen Huade Xinrun Equity Investment Enterprise, holds 77,288,400 shares, representing 28.01% of the total shares[12] - The company’s total number of shares repurchased as of now is 2,797,000, with a total payment of approximately RMB 48.60 million[17] - The highest transaction price for repurchased shares was RMB 19.09, while the lowest was RMB 15.76[17] Operational Performance and Future Outlook - The company aims to overcome operational challenges in Q2 2022 and maintain a good growth rate for the year despite the impact of the pandemic[7] - The company has partially resumed operations and is confident in making up for the first quarter shortfall through comprehensive production adjustments[7] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[26] Expenses - Total operating costs amounted to CNY 169,474,938.59, up 20.8% from CNY 140,288,213.40 in the same period last year[28] - Research and development expenses were CNY 20,677,466.87, slightly higher than CNY 20,115,688.19 in the previous year[28] - The company incurred a tax expense of 6,345,737.36, down from 8,108,870.03 in the previous year, representing a decrease of about 21.8%[34] Other Financial Metrics - The weighted average return on equity was 3.19%, down from 3.47% in the previous year[3] - The company reported a foreign exchange loss of -277,466.82, contrasting with a gain of 36,870.17 in the previous year[34] - The company reported a 116.79% increase in net cash flow from investing activities, totaling CNY 6,864,950.00, mainly due to the purchase of financial products[10] - The company experienced a 51.50% increase in prepayments, amounting to CNY 8,281,900.00, primarily due to increased raw material purchases[7] - Long-term receivables increased by 30.04%, reaching CNY 7,800,000.00, attributed to an increase in installment sales[7]

Financial Performance - Revenue for Q3 2021 was CNY 215,638,490.97, a decrease of 14.51% compared to the same period last year[6] - Net profit attributable to shareholders was CNY 46,265,700.72, down 63.64% year-on-year[6] - The company's operating revenue decreased by 11.47% year-on-year due to the sale of part of its equity in Ningbo Ruiyuan last year[20] - Net profit attributable to shareholders decreased by 33.65% year-on-year, while net profit excluding non-recurring gains and losses fell by 5.06%[20] - Total operating revenue for the current period is CNY 633,262,601.15, a decrease of 11.5% compared to CNY 715,333,738.21 in the previous period[32] - Net profit for the current period is CNY 156,184,874.19, a decrease of 38.6% compared to CNY 254,413,808.62 in the previous period[34] - The total comprehensive income attributable to the parent company was 156,120,603.29, a decrease from 235,239,776.13 in the previous period, representing a decline of approximately 33.5%[39] - Basic and diluted earnings per share were both 0.5666, down from 0.8587 in the previous period, indicating a decrease of about 33.9%[39] Cash Flow - Cash flow from operating activities decreased by 72.06% year-to-date, totaling CNY 43,281,876.33[6] - Cash inflow from operating activities totaled 623,975,763.80, compared to 808,786,155.20 in the previous period, reflecting a decrease of approximately 22.8%[40] - The net cash flow from operating activities was 43,281,876.33, down from 154,931,381.08, representing a decline of about 72.0%[43] - Cash inflow from investment activities was 92,548,750.00, an increase from 40,384,964.83 in the previous period, showing a growth of approximately 129.0%[43] - The net cash flow from investment activities was 86,857,867.41, up from 33,151,148.64, indicating an increase of about 161.0%[43] - Cash inflow from financing activities was 102,516,650.00, compared to 130,001,093.20 in the previous period, reflecting a decrease of approximately 21.1%[46] - The net cash flow from financing activities was -86,332,420.94, worsening from -48,898,089.78 in the previous period[46] - The cash and cash equivalents at the end of the period amounted to 714,682,086.12, an increase from 563,798,860.30 in the previous period, representing a growth of approximately 26.7%[46] Assets and Liabilities - Total assets increased by 5.43% from the end of the previous year, reaching CNY 2,133,316,018.85[6] - The total current assets as of September 30, 2021, amounted to approximately 1.26 billion, up from 1.20 billion at the end of 2020[24] - Total liabilities have increased to CNY 453,082,883.16 from CNY 368,947,823.47, marking a rise of about 22.7%[31] - The company's equity attributable to shareholders is CNY 1,680,233,135.69, up from CNY 1,654,500,366.12, reflecting an increase of approximately 1.6%[31] - The company has a total non-current asset of CNY 877,498,904.16, an increase from CNY 827,894,495.06, indicating a growth of about 6.0%[31] Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,459, with the top 10 shareholders holding a combined 85.51% of shares[13] - Shenzhen Huade Xinrun Equity Investment Enterprise holds 28.00% of shares, amounting to 77,288,400 shares, with 61,057,836 shares pledged[13] - Guangdong Hengjian International Investment Co., Ltd. holds 12.00% of shares, totaling 33,123,600 shares[13] - Song Jie, a natural person, holds 11.91% of shares, equating to 32,880,960 shares, with 24,660,720 shares under lock-up conditions[13] - The top three shareholders collectively own 51.91% of the company, indicating a significant concentration of ownership[13] - The report indicates that there are no preferred shareholders or changes in restricted shares during the period[17] - The company has a total of 1,487,000 restricted shares that are subject to stock incentive plans[17] - The report highlights that Song Yong and Song Jie are siblings, and Song Yong is married to Yi Xiangping, indicating potential related party transactions[16] - The company has not disclosed any other relationships among shareholders or whether they are acting in concert[16] Operational Insights - Accounts receivable increased by 38.46% compared to the beginning of the year, primarily due to increased credit sales to quality distributors[9] - Prepayments increased by 100.47% compared to the beginning of the year, mainly due to higher advance payments for raw materials[9] - Management expenses decreased by 38.05% year-on-year, mainly because Ningbo Ruiyuan was no longer included in the consolidated scope[9] - Investment income decreased by 64.99% year-on-year, primarily due to the investment income from Ningbo Ruiyuan in the previous year[9] - The company reported a decrease in other income by 49.48% year-on-year, primarily due to a reduction in government subsidies received[9] - Inventory increased to approximately 255.88 million from 218.42 million year-on-year, reflecting a strategic focus on product availability[24] - Long-term equity investments rose to approximately 397.54 million from 373.58 million year-on-year, indicating ongoing investment in strategic partnerships[24] - The company is in the process of localizing operations in international markets, which is expected to enhance sales of reagents[20] - The company established its domestic marketing headquarters in Beijing and increased its sales personnel by over 100 to enhance brand promotion[20] - The company has accumulated 204 patents, including 99 invention patents, indicating a strong focus on R&D and innovation[20] - The report does not mention any new product developments or market expansion strategies during this period[19] Audit and Compliance - The company did not undergo an audit for the third quarter report[47]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥417,624,110.18, a decrease of 9.82% compared to the same period last year[27]. - The net profit attributable to shareholders for the first half of 2021 was ¥109,919,173.47, an increase of 1.65% year-on-year[27]. - The net cash flow from operating activities decreased by 61.50% to ¥25,612,479.02 compared to the previous year[27]. - The total assets at the end of the reporting period were ¥2,062,128,726.70, reflecting a growth of 1.91% from the end of the previous year[27]. - The net assets attributable to shareholders decreased by 1.39% to ¥1,631,574,920.20 compared to the end of the previous year[27]. - The basic earnings per share for the first half of 2021 was ¥0.3978, a slight increase of 0.84% year-on-year[27]. - The weighted average return on net assets was 6.52%, down from 6.95% in the previous year[27]. - The gross margin for the first half of 2021 was reported at 60%, an increase from 55% in the same period last year[66]. - The gross margin improved to 45%, up from 40% in the previous year, due to cost optimization and increased operational efficiency[72]. Market Expansion and Strategy - International market revenue grew over 40% year-on-year, with significant increases in India and Brazil, surpassing pre-pandemic levels[38]. - The company is actively exploring external expansion opportunities, focusing on projects that align with its development direction, while assessing potential targets for valuation and growth[41]. - The company has expanded its products to over 120 countries, leveraging its marketing network to enhance international market growth, particularly in biochemical and urine analysis channels[52]. - The company is focusing on expanding its market presence through new product introductions in chemical luminescence, coagulation, and gynecology, which are expected to drive revenue growth[52]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[80]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies specializing in point-of-care testing technologies[86]. - The company plans to enhance its distribution network, aiming for a 50% increase in distribution points by the end of 2021[72]. Research and Development - The company continues to invest in R&D to enhance product variety and maintain sustainable profitability, focusing on self-developed products for market promotion[49]. - The company has allocated 200 million RMB for research and development in new technologies and products over the next two years[66]. - The company has invested 100 million RMB in R&D for innovative diagnostic technologies, aiming to improve testing accuracy and efficiency[72]. - The company has invested 200 million CNY in R&D for new technologies in the past year, focusing on automation and efficiency improvements[162]. - The company has a research and development team of 425 personnel, accounting for 26% of the total workforce[151]. - The company has obtained a total of 205 patents, including 92 invention patents, and 75 software copyrights as of June 30, 2021[151]. Product Development and Launches - The company launched the CSM-6000 biochemical immunoassay system and the MUS-4800 fully automated urine analysis line during the reporting period, enhancing its product offerings[164]. - New product launches include the CEA detection kit and NSE detection kit, both of which are expected to contribute significantly to future revenue streams[66]. - New product development includes the launch of 10 new diagnostic kits, which are expected to contribute significantly to revenue in the upcoming quarters[72]. - The company has introduced several new products, including a nucleic acid extraction kit and various blood analysis reagents, aimed at improving clinical testing capabilities[143]. - The company plans to launch three new products in the next quarter, including a fully automated biochemical analyzer and a urine analysis system[102]. Regulatory Compliance and Quality Control - The company adheres to the Shenzhen Stock Exchange's disclosure requirements for medical device businesses, ensuring transparency and compliance in its operations[55]. - The company’s quality management system has been certified by ISO9001 and ISO13485, ensuring high standards in product quality[165]. - The company is actively pursuing regulatory approvals for new products, which is essential for market expansion and competitiveness[75]. - The company has successfully registered several immunoassay products, including β-HCG and vitamin B12, enhancing its product portfolio in the immunology sector[164]. Challenges and Risks - The company faced risks and challenges as detailed in the management discussion and analysis section of the report[6]. - The company operates primarily on a distributor sales model, which poses risks related to contract renewals and distributor performance[195]. - The medical device industry is heavily regulated, and the company must adapt to ongoing policy changes to mitigate operational risks[200]. - The company faces risks related to new product and technology development, emphasizing the importance of maintaining technological leadership[194].

证券代码：300396 证券简称：迪瑞医疗 公告编号：2021-049 迪瑞医疗科技股份有限公司 关于参加网上集体业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，迪瑞医疗科技股份有限公司（以下简称 "公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有限公司 共同举办的"2021 年吉林辖区上市公司网上集体业绩说明会"，现将有关事项 公告如下： 本次集体业绩说明会将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参 与公司业绩说明会,时间为 2021 年 5 月 14 日（周五）15:30 至 17:00。 届时公司董事兼执行总经理郑国明先生、财务总监张兴艳女士、副总经理兼 董事会秘书安国柱先生将通过网络在线问答互动的形式，与投资者就 2020 年经 营业绩等投资者关注的问题进行交流。期间，公司高管将全程在线，实时回答投 资者的提问。欢迎广大投资者积极参与。 特此公告。 迪瑞医疗科技股份有限公司董事会 2021 年 5 ...

Financial Performance - The company's revenue for Q1 2021 was ¥198,572,194.45, representing a 14.82% increase compared to ¥172,939,800.45 in the same period last year[9] - Net profit attributable to shareholders was ¥58,429,472.14, a significant increase of 53.93% from ¥37,958,679.00 in the previous year[9] - The net profit after deducting non-recurring gains and losses was ¥56,891,974.75, up 53.73% from ¥37,008,604.53 year-on-year[9] - The basic earnings per share increased to ¥0.2132, reflecting a growth of 53.94% compared to ¥0.1385 in the same period last year[9] - The gross profit margin improved significantly, with operating profit increasing by 41.33% to 66.64 million yuan compared to the same period last year[26] - The company's net profit for the first quarter of 2021 is not explicitly stated in the provided documents, but the increase in retained earnings to CNY 1,036,626,245.82 from CNY 978,196,773.68 suggests positive performance[50] - The total comprehensive income attributable to the parent company was ¥58,466,342.31, up from ¥37,957,273.05, marking a 54% increase[69] Cash Flow - The net cash flow from operating activities decreased by 56.06% to ¥17,958,783.92 from ¥40,868,720.89 in the previous year[9] - The company's cash flow from operating activities generated a net inflow of ¥17,958,783.92, down from ¥40,868,720.89 in the previous period[79] - The net cash flow from operating activities was 16,521,283.28, a decrease of 37.2% compared to the previous period's 26,337,419.33[84] - Cash inflow from operating activities totaled 197,163,125.00, up 5.4% from 187,586,356.18 in the prior period[84] - Cash outflow from operating activities increased to 180,641,841.72, compared to 161,248,936.85 in the previous period, reflecting a rise of 12.0%[84] - The net cash flow from investing activities was 58,580,603.00, a significant improvement from the previous period's negative cash flow of -66,591,152.41[87] - The ending cash and cash equivalents balance was 737,856,599.25, up from 266,380,236.57 in the prior period, representing a substantial increase of 176.5%[87] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,058,741,321.44, a 1.74% increase from ¥2,023,448,189.59 at the end of the previous year[9] - The company's total assets increased to ¥2,012,528,184.90, compared to ¥1,977,308,150.56 in the previous period, marking a growth of 1.8%[57] - The total current liabilities decreased to CNY 316,967,676.61 from CNY 339,060,982.42, a reduction of about 6.5%[47] - The total liabilities decreased to CNY 345,774,613.01 from CNY 368,947,823.47, a decline of about 6.3%[47] - Total liabilities decreased to ¥343,620,808.57 from ¥366,304,794.46, a reduction of 6.2%[57] Shareholder Equity - Net assets attributable to shareholders increased by 3.53% to ¥1,712,966,708.43 from ¥1,654,500,366.12 at the end of the previous year[9] - The company's total equity attributable to shareholders reached CNY 1,712,966,708.43, up from CNY 1,654,500,366.12, marking an increase of approximately 3.5%[50] - The company's equity increased to ¥1,668,907,376.33, up from ¥1,611,003,356.10, reflecting a growth of 3.6%[57] Operating Costs and Expenses - The company experienced a 37.25% increase in operating costs, amounting to 23.93 million yuan, driven by higher product sales and agency product sales[21] - Total operating costs amounted to ¥140,288,213.40, up from ¥129,831,791.49, reflecting a rise of 7.5%[62] - Research and development expenses for the current period were ¥20,115,688.19, down from ¥22,554,378.11, a decrease of 10.8%[62] - Management expenses decreased by 50.32%, down by 10.05 million yuan, as Ningbo Ruiyuan was no longer included in the consolidation scope[21] Market Expansion - The international market export business grew by 80%, accounting for over 30% of total revenue, indicating strong international market expansion[26] - The company plans to enhance its product export business further as localization policies in international markets are implemented[26] Other Financial Metrics - The weighted average return on equity was 3.47%, up from 2.46% in the same period last year[9] - The company received government subsidies amounting to ¥1,786,202.85 during the reporting period[9] - The total number of ordinary shareholders at the end of the reporting period was 10,342[12] - Investment income surged by 5.85 million yuan, marking a staggering increase of 903.60% year-on-year, attributed to equity method accounting for Ningbo Ruiyuan[22]

Financial Performance - The company reported a cash dividend of 4.9 yuan per 10 shares (including tax) for the 2020 fiscal year[14]. - The company's operating revenue for 2020 was ¥937,235,915.34, a decrease of 7.09% compared to ¥1,008,790,834.99 in 2019[32]. - Net profit attributable to shareholders for 2020 was ¥267,071,664.29, representing a 15.17% increase from ¥231,892,235.08 in 2019[32]. - The net profit after deducting non-recurring gains and losses was ¥191,269,700.39, a decrease of 13.31% from ¥220,635,329.42 in 2019[32]. - The net cash flow from operating activities was ¥235,647,142.87, down 19.05% from ¥291,102,980.73 in 2019[32]. - Basic and diluted earnings per share for 2020 were both ¥0.9743, an increase of 15.23% from ¥0.8455 in 2019[32]. - Total assets at the end of 2020 were ¥2,023,448,189.59, a decrease of 1.88% from ¥2,062,321,454.32 at the end of 2019[32]. - The net assets attributable to shareholders increased by 8.50% to ¥1,654,500,366.12 from ¥1,524,884,729.44 at the end of 2019[32]. - The company reported non-recurring gains of ¥63,946,010.31 from the disposal of non-current assets in 2020[38]. - The company received government subsidies amounting to ¥15,319,056.98 in 2020, compared to ¥13,143,788.61 in 2019[38]. - The weighted average return on equity for 2020 was 16.92%, an increase from 16.07% in 2019[32]. Market and Sales Strategy - The company operates primarily on a dealer sales model, with revenue largely dependent on domestic and international dealers[8]. - The company has enhanced its sales efforts for terminal instrument products, resulting in an increase in instrument sales compared to the previous year, which positively impacted reagent sales[52]. - The company has completed the layout of its distribution network in major densely populated cities, focusing on new products such as gynecological and chemiluminescence analysis[49]. - The company’s product system covers over 80% of the demand in the in vitro diagnostic industry, with significant advantages in instrument products[53]. - The company has established localized teams in key markets through subsidiaries, enhancing domestic sales collaboration with major clients[52]. - The company is accelerating the market introduction of new products like the gynecological secretion analysis system and modular biochemical immunoassay system, which are expected to boost sales of reagents[53]. - The company has adopted a sales model primarily based on distributors, supported by direct sales, to expand its market presence[47]. - The company’s procurement strategy is based on sales plans and production needs, ensuring quality and cost-effectiveness in sourcing materials[50]. Research and Development - The company has accumulated significant core technologies over nearly 30 years, including automatic light tracking technology and anti-interference algorithms for urine analyzers[58]. - As of December 31, 2020, the company had 395 R&D personnel, accounting for 25% of the total workforce, and had obtained 197 patents, including 80 invention patents[58]. - The company has established a strong R&D team with expertise in various fields, including mechanics, optics, electronics, and clinical medicine[58]. - The company continues to focus on innovation and has developed numerous patented technologies for medical analysis instruments, enhancing its competitive edge in the market[58]. - The company achieved significant progress in R&D, focusing on biochemical analysis, urine analysis, blood cell analysis, gynecological secretion analysis, chemiluminescence immunoassay, and coagulation analysis, covering approximately 80% of routine hospital testing projects[68]. - Multiple product lines were developed simultaneously, including the CM-320i fully automated chemiluminescence immunoassay analyzer and the MUS-9600 fully automated urine analysis system, enhancing the product variety[68]. - The company is integrating existing product lines and deepening the R&D of chemiluminescence immunoassay, urine, biochemical, and blood products to ensure continuous new product offerings[68]. - The company has implemented several R&D projects across various product lines, indicating a robust innovation pipeline[68]. Regulatory Compliance and Quality Control - The medical device industry is heavily regulated, and the company must adapt to ongoing policy changes to avoid adverse impacts on operations[11]. - The company has established a comprehensive product quality management system to maintain high standards in product development and manufacturing[70]. - The company has received multiple certifications, including ISO9001, ISO13485, and NGSP, ensuring high-quality standards for its products[77]. - The company is committed to complying with the disclosure requirements for medical device businesses as per the Shenzhen Stock Exchange guidelines[103]. Product Development and Launches - The company launched 19 new authorized invention patents in 2020, bringing the total to 332 registered certificates[79]. - The company has registered and transitioned multiple models of analytical instruments and related test paper products, further enriching its product portfolio[68]. - The company is focused on expanding its product line with new testing kits aimed at various health conditions, including iron binding capacity and protein levels in urine[118]. - The company registered multiple new products, including urine analysis test strips and various reagent kits for biochemical analysis, all classified as Class II and Class I medical devices[179][182]. - The company has successfully registered several new products, including a total of 15 new diagnostic kits, enhancing its product portfolio and market competitiveness[125]. - The company aims to provide comprehensive diagnostic solutions, as evidenced by the introduction of various testing kits for hormones and biochemical markers[169]. Financial Outlook and Projections - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year 2020, representing a growth of 20% year-over-year[124]. - User data showed an increase in the number of tests conducted, with over 5 million tests performed using the company's products in 2020, up from 4 million in 2019, indicating a growth of 25%[124]. - The company has outlined its future outlook, projecting a revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[124]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 20% to 1.8 billion RMB[130]. - The company plans to invest 100 million RMB in R&D for the next fiscal year to accelerate innovation and product development[124]. - Future guidance suggests a revenue growth target of 12-15% for the next fiscal year, driven by new product launches and market expansion efforts[181].

Financial Performance - Net profit attributable to shareholders was CNY 127,250,496.02, an increase of 99.92% year-on-year[9]. - Operating income for the period was CNY 252,239,693.25, representing a year-on-year increase of 5.56%[9]. - Basic earnings per share reached CNY 0.4642, up 99.91% compared to the same period last year[9]. - The company reported a significant increase in investment income of CNY 681.03 million, a growth of 19526.53%, due to the disposal of an 11% stake in Ningbo Ruiyuan[26]. - The company reported an increase in non-operating income by 2,173,400 CNY year-to-date, an increase of 68.45%, mainly due to increased government subsidies received[8]. - The company reported a total comprehensive income attributable to the parent company of CNY 127,094,383.35, compared to CNY 63,651,419.13 in the previous period, showing a 99.5% increase[74]. - The company reported a financial expense of CNY -2,051,021.37, an improvement from CNY -5,904,637.62 in the previous period[84]. Cash Flow - The net cash flow from operating activities was CNY 88,406,306.54, an increase of 18.87% year-on-year[9]. - Cash and cash equivalents increased by CNY 135.74 million, a growth of 30.14%, primarily due to cash flow generated from operating activities[26]. - The total cash and cash equivalents at the end of the period increased to CNY 558,330,713.59, up from CNY 251,848,174.02 at the end of the previous period[107]. - Cash inflow from sales of goods and services was CNY 602,099,416.67, a decrease of 2.9% from CNY 618,031,358.95 in the previous period[104]. - Cash received from investment activities totaled CNY 164,310,069.07, significantly higher than CNY 77,414,786.10 in the previous period[104]. - The net increase in cash and cash equivalents for the period was CNY 251,973,096.07, a significant increase from CNY 3,586,257.39 in the previous period[107]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,040,730,098.05, a decrease of 1.05% compared to the end of the previous year[9]. - Total liabilities increased to CNY 417,666,892.48 from CNY 327,532,396.99, reflecting a growth of 27.5%[54]. - The company's total assets decreased slightly to CNY 2,040,730,098.05 from CNY 2,062,321,454.32, a reduction of 1.0%[57]. - The company's equity attributable to shareholders increased to CNY 1,623,063,205.57 from CNY 1,524,884,729.44, an increase of 6.5%[57]. - Total liabilities amounted to 327,532,396.99, with current liabilities at 267,334,481.76[114]. - The company reported accounts payable of 55,900,077.27, which is a critical component of its working capital[122]. Shareholder Information - The total number of shareholders at the end of the reporting period was 11,281, with the largest shareholder holding 53.80% of the shares[14]. - The company did not engage in any repurchase transactions during the reporting period[17]. Investment Activities - Long-term equity investments increased by CNY 432.56 million, primarily due to the change in accounting method for Ningbo Ruiyuan[26]. - The company completed the transfer of 11% equity in its subsidiary, reducing its ownership from 51% to 40%, which will no longer be included in the consolidated financial statements[32]. - The company is undergoing a potential change in control, with significant shareholders planning to transfer at least 25% of their shares to a wholly-owned subsidiary of China Resources Group[33]. Research and Development - Research and development expenses for the quarter were CNY 25,074,656.85, compared to CNY 21,792,112.79 in the previous year, showing an increase of 15.5%[67]. - The company plans to continue focusing on R&D and market expansion strategies to enhance future performance[85]. Changes in Financial Position - The company reported a decrease in net profit excluding non-recurring items by 9.35% year-on-year, totaling CNY 55,147,421.06[9]. - The company's goodwill decreased by CNY 397.20 million, a reduction of 100%, due to the exclusion of Ningbo Ruiyuan from the consolidated financial statements[26]. - The fair value change income for the year-to-date decreased by 817,200 CNY, a decline of 89.99%, mainly due to a reduction in unexpired financial products[8]. - Credit impairment losses increased by 799,000 CNY year-to-date, with a change rate of -586.37%, primarily due to a decrease in bad debt provisions[8]. - Asset impairment losses increased by 3,182,100 CNY year-to-date, with a change rate of -93.73%, mainly due to a reduction in inventory write-down provisions[8].

证券代码：300396 证券简称：迪瑞医疗 公告编号：2020-105 迪瑞医疗科技股份有限公司 关于参加投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，迪瑞医疗科技股份有限公司（以下简称 "公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有限公司 共同举办的"提高公司质量 做受尊敬的上市公司--2020 年吉林辖区上市公司 投资者网上集体接待日"活动，现将有关事项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景·路演天下"网站（http://rs.p5w.net）参与公司 本次投资者集体接待日活动,时间为 2020 年 8 月 21 日（周五）15:30 至 17:00。 届时公司董事兼总经理郑国明先生、财务总监张兴艳女士、副总经理兼董事 会秘书安国柱先生将通过网络在线问答互动的形式，与投资者就公司治理、发展 经营情况、融资情况和可持续发展等投资者关注的问题进行交流。期间，公司高 管将全程在线，实时回答投资者的提问。欢迎广大投资者 ...

Financial Performance - The company's operating revenue for the reporting period was ¥463,094,044.96, a decrease of 6.18% compared to the same period last year[29]. - The net profit attributable to shareholders was ¥108,133,673.82, down 14.12% year-on-year[29]. - The net profit after deducting non-recurring gains and losses was ¥105,459,501.28, reflecting a decrease of 12.97% compared to the previous year[29]. - The net cash flow from operating activities was ¥66,525,074.54, a significant decline of 47.49% from the same period last year[29]. - The total assets at the end of the reporting period amounted to ¥2,146,748,609.07, representing an increase of 4.09% compared to the end of the previous year[29]. - The net assets attributable to shareholders decreased to ¥1,495,968,822.22, down 1.90% from the previous year[29]. - The operating profit was 134.28 million yuan, down 17.24% year-on-year, while the total profit was 132.61 million yuan, a decline of 18.66% compared to the previous year[75]. - The gross margin for the first half of 2020 was reported at 45%, reflecting improved operational efficiencies[98]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2020, representing a year-over-year growth of 20%[98]. Research and Development - The company has a total of 492 R&D personnel, accounting for 27% of the total workforce[55]. - The company has obtained a total of 202 patents, including 89 invention patents and 63 software copyrights as of June 30, 2020[55]. - R&D investment for the reporting period was approximately 52.72 million yuan, compared to 57.49 million yuan in the same period last year[79]. - The company is focusing on the development of new products, including the CM-320i fully automated chemiluminescence immunoassay analyzer and MUS-9600 fully automated urine analysis system, to enhance its product offerings[78]. - The company is committed to enhancing its product portfolio through continuous research and development efforts[55]. - The company is actively engaged in the development of new products and technologies, including automatic focusing methods for microscope systems and automatic sample supply devices for blood analysis[55]. - The company has launched a series of new products in biochemical analysis, urine analysis, blood cell analysis, coagulation analysis, and modular biochemical immunoassay systems, further enriching its product offerings[65]. Market Expansion and Strategy - The company is expanding its market presence through innovative product offerings and technological advancements in medical diagnostics[55]. - The company has established a sales and service network in over 70 cities domestically and has expanded its products to over 120 countries and regions globally[74]. - The company is focusing on enhancing its competitive position in the urine and biochemical analysis markets, with new product lines expected to drive sales growth[51]. - The company plans to adapt its sales model in response to new product circulation management policies and market demands[43]. - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2021[98]. - The company is exploring potential acquisitions to enhance its product portfolio, focusing on firms with complementary technologies in the medical diagnostics field[119]. Product Quality and Compliance - The company emphasizes the importance of product quality in its in vitro diagnostic devices, as quality issues could lead to product returns and financial losses[6]. - The quality management system has been certified by ISO9001 and ISO13485, ensuring high standards throughout the research, procurement, production, and sales processes[68]. - The company is committed to maintaining product quality that exceeds national standards[68]. - The company is committed to ensuring the accuracy of its products and is actively involved in the quality control of tumor markers[174]. - The company is focused on meeting regulatory standards to facilitate the launch of new products in both domestic and international markets[159]. Risks and Challenges - The company faces risks related to its distributor model, which primarily relies on annual contracts with distributors, affecting revenue stability[5]. - The company is exposed to regulatory risks in the medical device industry, which could impact its marketing strategies and operational environment[9]. - The company’s main business is affected by the COVID-19 pandemic, which could disrupt logistics and sample volumes from hospitals, negatively impacting reagent sales[9]. - The company’s future plans and forecasts are subject to risks, and investors are advised to recognize the differences between plans, forecasts, and commitments[5]. Future Outlook - The company has provided a positive outlook for the second half of 2020, projecting a revenue growth of 25% driven by new product launches and market expansion efforts[98]. - The company anticipates a positive outlook for the next fiscal year, driven by new product launches and market expansion strategies[149]. - The company has set ambitious performance guidance for the upcoming quarters, aiming for a revenue growth of over 20% year-on-year[116]. - The company expects revenue growth of 20% for the second half of 2020, driven by new product launches and market expansion efforts[182].

Financial Performance - Total revenue for Q1 2020 was ¥172,939,800.45, a decrease of 26.06% compared to ¥233,879,595.66 in the same period last year[9] - Net profit attributable to shareholders was ¥37,958,679.00, down 21.03% from ¥48,070,157.71 year-on-year[9] - Basic and diluted earnings per share were both ¥0.1385, reflecting a decline of 20.86% compared to ¥0.1750 in the same period last year[9] - Operating income decreased by 60.94 million RMB, a decline of 26.06%, mainly due to reduced sales of reagents impacted by the COVID-19 pandemic[25] - Operating profit for the same period was 47.15 million yuan, down 26.42% year-on-year, while net profit attributable to shareholders was 37.96 million yuan, reflecting a 21.03% decline[32] - Total operating revenue for the first quarter was CNY 172,939,800.45, a decrease of 26% compared to CNY 233,879,595.66 in the same period last year[61] - Total profit amounted to ¥45,479,498.20, down 29.1% from ¥64,219,576.24 in the previous period[67] - Net profit for the current period was ¥39,708,097.55, a decline of 29.4% from ¥56,203,675.37 in the previous period[67] Cash Flow - Net cash flow from operating activities decreased by 38.98% to ¥40,868,720.89 from ¥66,972,238.48 in the previous year[9] - Cash inflow from operating activities totaled CNY 240,699,812.46, down from CNY 302,039,814.29 in the prior period, indicating a decline of approximately 20.3%[78] - Cash paid for purchasing goods and services decreased by 36.49 million RMB, a decline of 33.55%, mainly due to reduced inventory purchases impacted by the COVID-19 pandemic[30] - Cash outflow from investment activities was CNY 121,991,589.23, significantly higher than CNY 2,836,948.43 in the prior period, resulting in a net cash flow from investment activities of -CNY 66,304,903.78[87] - The company reported a net cash outflow from financing activities of -CNY 468,902.78, compared to -CNY 35,685,620.99 in the prior period, indicating improved cash flow management[84] Assets and Liabilities - Total assets increased by 3.15% to ¥2,127,244,734.39 from ¥2,062,321,454.32 at the end of the previous year[9] - The total liabilities increased to CNY 314,686,592.73 from CNY 281,344,685.25, reflecting a growth of approximately 12.5%[59] - The total equity attributable to shareholders rose to CNY 1,509,998,103.49, up from CNY 1,473,836,658.59, indicating an increase of about 2.4%[59] - The company’s total liabilities and equity amounted to CNY 2,127,244,734.39, up from CNY 2,062,321,454.32, indicating an increase of approximately 3.2%[52] - Total current assets were CNY 968,975,003.35, with cash and cash equivalents at CNY 450,327,054.60[92] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,262[13] - The largest shareholder, Changchun Ruifa Investment Co., Ltd., held 53.80% of the shares, totaling 148,500,000 shares[13] - The company approved a plan for issuing convertible bonds to raise funds, with the board meeting held on March 30, 2020, and the shareholder meeting on April 15, 2020[33][35] Operational Changes - The company increased its sales staff to support pandemic response efforts and donated medical supplies, which impacted overall profit levels due to a decline in reagent sales[32] - The company engaged in large-scale procurement projects, with some orders extending into the second quarter due to capacity and material constraints[32] - The company maintained a balanced development strategy between instruments and reagents, expanding both domestic and international markets[32] Other Financial Metrics - The company reported government subsidies recognized in the current period amounting to ¥1,625,641.84[12] - Other income increased by 2.02 million RMB, a growth of 218.13%, mainly due to an increase in VAT refunds received during the reporting period[26] - Investment income increased by 0.51 million RMB, a growth of 361.59%, primarily due to increased returns from financial products during the reporting period[26] - Cash received from tax refunds increased by 0.88 million RMB, a growth of 266.98%, mainly due to increased VAT refunds during the reporting period[27] - The company reported a significant increase in long-term receivables by 6.72 million RMB, a growth of 38.60%, mainly due to an increase in installment payment business during the reporting period[24]